Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegasys plus higher-dose versus standard-dose Copegus in HCV genotype 1/HIV-1 coinfected adults
2005-005506-23Phase 4Completed
- Sponsor
- Roche
- Start
- Mar 2006
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of interferon alfa and ribavirin in chronic hepatitis C virus infection and Human immunodeficiency virus infection type 1 (2 arms), sponsored by Roche. Primary endpoint: Sustained virologic response. Started Mar 2006; status: completed.
02
Drugs
interferon alfaribavirin
03
Conditions
chronic hepatitis C virus infectionHuman immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2005-005506-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005506-23.